These were the biggest pharmaceutical deals in early 2022
GlobalData tracks the latest acquisitions, mergers, venture financing and asset transactions in the pharmaceutical sector.
By
GlobalData tracks the latest acquisitions, mergers, venture financing and asset transactions in the pharmaceutical sector.
ByOn Taiho acquiring Cullinan Pearl, Cullinan Oncology is entitled to receive $275m in upfront payment.
Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.
AnGes will make upfront and milestone payments up to $1.5m to Eiger, under the deal.
According to the deal, Pfizer will acquire CGRP programmes of Biohaven, including rimegepant, zavegepant and five pre-clinical assets.
This alliance is the third academic-industry partnership of API this year to develop therapies against viral variants.
The data shows that M&A activity is strongest in the US, which saw a total of 19 deals announced in…
ByAstellas will handle the development, production and marketing of any licenced products developed out of the partnership.